These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 27641225)
1. Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Visentin A; Gurrieri C; Imbergamo S; Lessi F; Di Maggio SA; Frezzato F; Adami F; Zambello R; Piazza F; Semenzato G; Trentin L Hematol Oncol; 2017 Dec; 35(4):925-928. PubMed ID: 27641225 [No Abstract] [Full Text] [Related]
2. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. Mozas P; Rivas-Delgado A; Baumann T; Villamor N; Ortiz-Maldonado V; Aymerich M; Costa D; Navarro A; Giné E; López-Guillermo A; Montserrat E; Delgado J Blood Cancer J; 2018 Jan; 8(1):10. PubMed ID: 29339727 [No Abstract] [Full Text] [Related]
3. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. Tedeschi A; Rossi D; Motta M; Quaresmini G; Rossi M; Coscia M; Anastasia A; Rossini F; Cortelezzi A; Nador G; Scarfò L; Cairoli R; Frustaci AM; Dalceggio D; Picardi P; De Paoli L; Orlandi E; Rambaldi A; Massaia M; Gaidano G; Montillo M; Haematologica; 2015 Dec; 100(12):e501-4. PubMed ID: 26294723 [No Abstract] [Full Text] [Related]
4. Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia. Ayyildiz O; Isikdogan A; Bolaman Z; Muftuoglu E Saudi Med J; 2004 Dec; 25(12):2054-6. PubMed ID: 15711709 [No Abstract] [Full Text] [Related]
5. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia. Henn A; Mellon G; Benoît H; Roos-Weil D; Jauréguiberry S; Mordant P; Fekkar A; Caumes E Scand J Infect Dis; 2014 Mar; 46(3):231-4. PubMed ID: 24450842 [TBL] [Abstract][Full Text] [Related]
6. Long-term survival among patients with chronic lymphocytic leukemia (CLL) treated in Department of Hematology, Medical University of Lublin. Sokołowska B; Wasik E; Kniaź M; Brzozowska J; Podhorecka M; Sledzińska M; Domański D Ann Univ Mariae Curie Sklodowska Med; 2000; 55():103-9. PubMed ID: 11482058 [No Abstract] [Full Text] [Related]
7. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature. Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794 [TBL] [Abstract][Full Text] [Related]
8. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Teh BW; Teng JC; Urbancic K; Grigg A; Harrison SJ; Worth LJ; Slavin MA; Thursky KA Haematologica; 2015 Jan; 100(1):e28-31. PubMed ID: 25304609 [No Abstract] [Full Text] [Related]
9. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606 [TBL] [Abstract][Full Text] [Related]
10. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Elter T; James R; Busch R; Winkler D; Ritgen M; Böttcher S; Kahl C; Gassmann W; Stauch M; Hasan I; Staib P; Fischer K; Fink AM; Bahlo J; Bühler A; Döhner H; Wendtner CM; Stilgenbauer S; Engert A; Hallek M Leukemia; 2012 Dec; 26(12):2549-52. PubMed ID: 22584787 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A; Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442 [TBL] [Abstract][Full Text] [Related]
12. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006 [TBL] [Abstract][Full Text] [Related]
13. FCA: forget chemoimmunotherapy with alemtuzumab? Hallek M Blood; 2012 May; 119(22):5059-60. PubMed ID: 22653949 [No Abstract] [Full Text] [Related]
14. Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. St Bernard R; Hsia CC Ann Hematol; 2015 Dec; 94(12):2077-9. PubMed ID: 26334319 [No Abstract] [Full Text] [Related]
15. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Fornecker LM; Aurran-Schleinitz T; Michallet AS; Cazin B; Guieze R; Dilhuydy MS; Zini JM; Tomowiak C; Lepretre S; Cymbalista F; Brion A; Feugier P; Delmer A; Leblond V; Ysebaert L Am J Hematol; 2015 Jun; 90(6):511-4. PubMed ID: 25752923 [TBL] [Abstract][Full Text] [Related]